General Information of Drug (ID: DMQUSXK)

Drug Name
PTI-601 Drug Info
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Investigative [1]
Cross-matching ID
TTD Drug ID
DMQUSXK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [3]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [4]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [5]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [3]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [6]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [7]
Tapentadol hydrochloride DMXLSH3 Acute pain MG31 Approved [8]
Venlafaxine DMR6QH0 Anxiety disorder 6B00-6B0Z Approved [7]
Trimipramine DM1SC8M Major depressive disorder 6A70.3 Approved [9]
Duloxetine DM9BI7M Depression 6A70-6A7Z Approved [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Opioid receptor mu (MOP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [11]
Morphine DMRMS0L Advanced cancer 2A00-2F9Z Approved [12]
Hydromorphone DMHP21E Back pain ME84.Z Approved [13]
Tapentadol hydrochloride DMXLSH3 Acute pain MG31 Approved [8]
Fentanyl DM8WAHT Analgesia MB40.8 Approved [14]
Alfentanil DMVO0UB Anaesthesia 9A78.6 Approved [15]
Naloxegol DML0B41 Opioid-induced constipation DB32.1 Approved [16]
Eluxadoline DMYZ0P1 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [17]
Nalfurafine hcl DMA9DHW Uremic pruritus EC90.10 Approved [18]
Oxycodone DMXLKHV Osteoarthritis FA00-FA05 Approved [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [2]
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Modulator [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
3 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
4 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
5 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
6 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
7 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
8 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
9 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
10 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
11 Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
12 Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
13 Clinical pipeline report, company report or official report of signaturerx.
14 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
15 Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
16 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
17 Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
18 Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.